Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mSIRK
- Development stage
- Unknown
- Modality
- Peptides
- Administration
- Intravenous, Parenteral
01
Overview
mSIRK is a cell-permeable, myristoylated peptide that serves as a direct and specific activator of G-protein βγ (Gβγ) subunits. It is primarily utilized as a pharmacological research tool to investigate Gβγ-mediated signaling pathways independently of G-protein-coupled receptor (GPCR) activation. By binding to Gβγ subunits, mSIRK induces the dissociation of the Gαβγ heterotrimer, thereby triggering downstream effectors such as phospholipase C (PLC) and stimulating calcium influx from the extracellular space. In oncological research, particularly melanoma, mSIRK has been demonstrated to inhibit Epac-induced cell migration by modulating intracellular calcium dynamics and crosstalking with calmodulin-dependent pathways.
- Other names
- myristoylated SIRK peptideSIRK peptide
02
Targets
Gβγ (G protein beta-gamma subunit complex)
Beyond the preview
Go deeper on mSIRK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mSIRK.